Accuracy of $p57^{KIP2}$ compared with genotyping for the diagnosis of complete hydatidiform mole: protocol for a systematic review and meta-analysis

Jose Mauro Madi$^{1,2,*}$, Antonio Rodrigues Braga$^{2,3}$, Machline Paim Paganella$^{4}$, Isnard Elman Litvin$^{1}$ and Eliana Márcia Da Ros Wendland$^{5}$

Abstract

Background: Distinguishing hydatidiform moles (HMs) from non-molar specimens and the subclassification of HM are important because complete hydatidiform mole (CHM) is associated with an increased risk of gestational trophoblastic neoplasia. However, diagnosis based solely on morphology has poor interobserver reproducibility. Recent studies have demonstrated that the use of $p57^{KIP2}$ immunostaining improves diagnostic accuracy for CHM.

Methods: We will conduct a systematic review of prospective and retrospective studies to evaluate the accuracy of $p57^{KIP2}$ immunostaining compared with molecular genotyping for the diagnosis of CHM. A high-sensitivity search strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data. The methodological quality and bias of the included studies will be assessed according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, and the overall quality of evidence will be assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. If a meta-analysis is possible, pooled estimates of sensitivity, specificity, and positive and negative likelihood ratios will be calculated using bivariate random-effects models. Statistical heterogeneity will be evaluated with $I^2$ statistics and explored through sensitivity analysis.

Discussion: There is considerable overlap between the histological features of molar and non-molar pregnancies and between complete and partial HMs, which results in significant interobserver variability in the diagnosis of CHM and its mimics. Therefore, molecular techniques are used to correctly diagnose and treat CHM. However, these molecular diagnostic methods are technically difficult to perform, relatively costly, and unavailable in most pathology laboratories. According to our results, $p57^{KIP2}$ immunostaining appears to be a practical and accurate adjunct for the diagnosis of CHM and its mimics because this technique is relatively simple, reliable, cost-efficient, and rapid. This systematic review will help to determine whether $p57^{KIP2}$ immunostaining is an adequate alternative diagnostic test for CHM.

Systematic review registration: PROSPERO CRD42015024181

Keywords: Complete hydatidiform mole, $p57$ immunohistochemistry, Molecular genotyping, Protocol, Systematic review, Meta-analysis

* Correspondence: jmmadi@ucs.br

1School of Medicine, Center for Biological and Health Sciences – CCBS, Caxias do Sul University - UCS, Rua Francisco Getúlio Vargas, 1130, Bloco S, Caxias do Sul, RS CEP 95070-560, Brazil

2Maternity School, Federal University of Rio de Janeiro – UFRJ, Rua das Laranjeiras, 180, Rio de Janeiro, RJ CEP 22240-003, Brazil

Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Description of the condition

Hydatidiform mole (HM) is an abnormal gestational condition characterized by significant hydropic enlargement and variable trophoblastic proliferation involving part or all of the chorionic villi. Histopathological examination remains the basis for the diagnosis of HM; however, the diagnosis and classification of HM has become increasingly difficult because HMs are now commonly evacuated at an earlier stage and do not satisfy the well-established classic morphological features [1]. Previous studies have demonstrated that the diagnosis of HM based on morphology alone is subject to interobserver variability and therefore suboptimal diagnostic reproducibility [2, 3]. Differentiating a molar pregnancy from non-molar specimens and the classification of HM as complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), early CHM (eCHM) or hydropic abortion (HA) is important for both clinical practice and investigational studies because the risk of persistent gestational trophoblastic disease, including choriocarcinoma, is significantly higher after a pregnancy affected by CHM (10–30 %) or PHM (0.5–5 %) compared with any other pregnancy [2–4].

The p57KIP2 gene is paternally imprinted and maternally expressed, and the presence of its protein product serves as a surrogate marker for the nuclear maternal genome. CHM is the only type of conceptus lacking a maternal contribution, and p57KIP2 immunostaining is accordingly absent, whereas it is present in CHM mimics [4].

Description of the index test

The index test will consist of p57KIP2 immunostaining. P57KIP2 immunostaining is an in situ technique performed on paraffin-embedded tissue. The results usually are easy to interpret. P57 is a cyclin-dependent kinase inhibitor and tumour suppressor gene located on chromosome 11p15.5. The lack of p57KIP2 activity can lead to a loss of cell cycle control, which results in the abnormal proliferation and differentiation of trophoblasts in CHM. As expected, a lack of the p57KIP2 protein product has been demonstrated in immunohistochemistry (IHC)-based studies on CHMs, but not in those on non-CHMs, which suggests that p57KIP2 IHC can be helpful for distinguishing CHM from its mimics. The p57KIP2 gene (CDKN1C) is a strongly paternally imprinted gene that is expressed only by the maternal allele in most tissues and is involved in implantation. P57KIP2 immunostaining is absent in CHM due to the lack of a maternal genome [1].

Explanations for the negative expression of p57KIP2 in discordant cases include misdiagnosed CHM, false-negative results in a non-CHM patient, or a lack of staining due to loss of antigenicity. False-positive staining is attributed to the retention of maternal chromosome 11, which is a phenomenon that is rarely seen in CHM [1]. Immunostaining is assessed in the nuclei of the villous mesenchymal cells (VMC) and cytotrophoblasts. Positive immunostaining is considered to exist when more than 10 % of the nuclei of the cytotrophoblasts and VMC are stained. Immunostaining of extravillous trophoblast cells, trophoblastic cells within cell columns or islands, and interstitial trophoblasts at the maternal-foetal junctional zones are observed as internal positive controls. Syncytiotrophoblastic cells are used as negative controls [1, 2, 4]. It was recently demonstrated that p57KIP2 immunostaining can be helpful for refining the diagnosis of some morphologically challenging cases and for the detection of androgenetic cell lines in mosaic/chimeric conceptions [1]. There are rare examples where the morphology and immunophenotype (p57-negative) of CHM occur in patients with familial recurrent HMs associated with mutations in NLRP7 (NALP7) or KHDC3L (C6orf221) [4].

Description of the standard test

Genotyping, which is accomplished through PCR amplification of short tandem repeat loci, is particularly valuable for the diagnosis of HM because it allows the specific distinction of CHM, PHM, eCHM, and HA. Through genotyping, CHM is diagnosed based on the finding of purely androgenetic alleles. The vast majority of CHMs are characterized by androgenetic diploidy (two sets of paternal chromosome complements without a maternal chromosome complement); however, a small subset can exhibit androgenetic tetraploidy (genotyping does not specifically distinguish examples of diploidy from tetraploidy because peak heights do not indicate the actual DNA content) [4]. Analysis of nuclear DNA microsatellite polymorphisms is particularly well suited for the diagnosis of MHC because it is capable of determining the number and parental origin of alleles. Molecular diagnostic methods such as genotyping are limited because they are technically difficult, relatively costly, and not universally available. In addition, ploidy analysis does not differentiate between CHM and HA because both are diploid. It has been reported that CHM results from the fertilization of an enucleated egg by a haploid sperm, followed by duplication of the sperm genome (homozygous). However, in approximately 10–25 % of cases, the enucleated egg is fertilized by two sperm cells (heterozygous). In some cases diagnosed using microsatellite genotyping, androgenic CHM can be misdiagnosed as biparental mole, containing maternal alleles, due to possible contamination of the molar tissue by maternal tissue that was inadvertently sent for analysis. Analyses of genotyping results can be difficult to interpret if abundant tissue of maternal origin is present. Genotyping analysis plays an important role in
the diagnosis of challenging cases with unusual p57\textsuperscript{KIP2} results [1, 4]. The goals of this systematic review are to generate new quantitative evidence for clinicians and to establish the accuracy of p57\textsuperscript{KIP2} IHC compared with genotyping for the identification of CHM.

**Methods**

**Design**

The methodological approach for evidence searching and synthesis described in this protocol will conform to the Cochrane Collaboration's methods for assessing diagnostic test accuracy [5]. We will also follow the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) included as an additional file (Additional file 1) [6].

The study is registered at PROSPERO, the International Prospective Register of Systematic Reviews, at the University of York (CRD42015024181).

**PIRO question**

For analyses of the diagnostic accuracy of research questions, the acronym PIRO is used, corresponding to P (population), I (index test), R (reference standard), and O (outcome).

The definitions of the components of the PIRO acronym for this systematic review are as follows:

- Population: women of reproductive age (14–50 years)
- Index test: p57\textsuperscript{KIP2} immunohistochemistry
- Reference standard: genotyping
- Outcome: MHC identification.

**Search methods for identifying studies**

Keywords and Medical Subject Headings related to HM, p57\textsuperscript{KIP2} and molecular genotyping will be used alone or in combination (together with synonyms and closely related words) to retrieve the relevant articles.

We will conduct searches in the Excerpta Medica Database (EMBASE), Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud (LILACS), Medical Literature Analysis and Retrieval System Online (MEDLINE), Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science. We will also screen the reference lists of relevant studies and reviews for additional articles and will search the grey literature websites The Grey Literature Report, OpenGrey, and the Open Archives Initiative (OAIster). If necessary (in the case of unclear data, missing data or extractable data), we will attempt to contact the corresponding authors of the included studies for missing data and for clarification. The search strategy developed for MEDLINE (see Additional file 2) will be adapted for the other databases. There will be no language or publication year restriction.

**Eligibility criteria for the included studies**

Any cross-sectional study, case series, case-control study, cohort study, or clinical trial that evaluates the accuracy of p57\textsuperscript{KIP2} immunostaining for the diagnosis of CHM compared with genotyping will be included. Case reports, narrative reviews, and expert opinions will be excluded. Animal testing will be excluded.

**Data collection**

Two independent researchers will evaluate the titles and abstracts arising from the combined search and will independently extract all data from the retrieved articles using a predefined data extraction sheet. A third author will adjudicate any discrepancies.

In the case of duplicate publications or more than one publication from a preliminary study, we will attempt to maximize the use of the information by simultaneously evaluating all of the available data, but we will not include the same group of patients in the analysis more than once.

The data will be extracted in the form of a data sheet specifically developed for this analysis (Tables 1 and 2). The following information will be extracted from each study, with the possibility of adding further information during the extraction process when appropriate:

- Study characteristics: title, author, country, design, language of publication, year of publication, sample size, and number of centres
- Population characteristics: total number of patients, number of patients in groups for comparison, and age of the patients
- Index test: type of test and diagnostic criteria
- Standard test: type of test and diagnostic criteria
- Outcomes: number of true positives, false positives, true negatives, and false negatives, sensitivity and specificity, negative predictive value (NPV) and positive predictive value (PPV), and the positive likelihood ratio (LR+) and negative likelihood ratio (LR−)

If there are any missing or insufficient data in the included studies, we will contact the corresponding authors of the studies via email to obtain additional information. When more than one threshold is available, all data will be included.

| # | Author Year | Country | Language | Study design | Age | CHM/ IHC | CHM/ Geno | # of centers |
|---|-------------|---------|----------|-------------|-----|---------|----------|-------------|
| 1 |             |         |          |             |     |         |          |             |
| 2 |             |         |          |             |     |         |          |             |
| 3 |             |         |          |             |     |         |          |             |
| 4 |             |         |          |             |     |         |          |             |

CHM complete hydatidiform mole, IHC immunohistochemistry, Geno genotyping
be recorded. A sensitivity analysis will be conducted to assess the impact of including studies with 20 % or more missing data.

Risk of bias assessment
We will assess the quality of the studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [7]. If necessary, QUADAS-2 will be adapted to fit different study designs included in accordance with our research question. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) will be used to rate the quality of the body of evidence retrieved in the search [8].

Outcomes
The primary outcome will be the diagnostic accuracy of p57KIP2 immunostaining for the diagnosis of CHM, which will be described based on sensitivity and specificity, negative and positive predictive values, and positive and negative likelihood ratios wherever possible.

Statistical analysis
Where the data permit, we will compare the index test against the reference test. For each study, we will extract the number of true positives, true negatives, false positives, and false negatives. When the raw data are provided, contingency tables will be built to display the results of the tests. The test results will be treated as positive or negative for the cut-off values of the index test. The sensitivity, specificity, positive predictive value, false-positive rate, and positive likelihood ratio will be calculated from the cut-off values of the index test. Forest plots will be generated to illustrate sensitivity and specificity (SROC) will be calculated based on methods described by Deeks et al. [15].

Between the bivariate random-effects model [12] and the HSROC model from Rutter et al. [13] will be based on the presence of different thresholds. Both approaches can be used to compute estimates of the summary ROC curve and the average operating point and allow us to determine the extent of heterogeneity in the estimated pooled measure. If heterogeneity is detected, we will conduct a subgroup analysis and meta-regression to evaluate the impact of the covariates in the pooled estimation. The two models are mathematically equivalent when no covariates are included in the model.

The magnitude of heterogeneity will be assessed using Cochran's Q statistic and Higgins I² statistic, where an I² greater than 50 % indicates the presence of significant heterogeneity. The I² statistic will be calculated according to the following equation: $I^2 = 100 \% \times (Q - df)/Q$, where $Q$ is the Cochran heterogeneity statistic [14]. If quantitative synthesis is not appropriate, a descriptive analysis might be undertaken.

We will perform a sensitivity analysis to examine the effect of sample size and missing data on the results of the review. If there are adequate studies (no less than three studies), we will conduct a sensitivity analysis to check the robustness of the conclusions and assess the impact of the methodological quality.

The presence of publication bias will be assessed by performing a regression of lnDOR and the effective sample size (ESS) based on methods described by Deeks et al. [15].

Discussion
There is considerable overlap in histological features between molar and non-molar pregnancies and between CHMs and PHMs, which results in significant interobserver variability in the diagnosis of HM and its mimics. Therefore, correct diagnosis of these difficult cases may require molecular techniques that examine the differences in DNA content between CHM and PHM, including flow hybridization, polymerase chain reaction-based genotyping, or HLA typing. However, these molecular diagnostic methods are technically difficult to perform, relatively costly, and unavailable in most pathology laboratories [1].

Banet et al. established that immunohistochemical analysis of p57KIP2 expression is highly correlated with genotyping results and demonstrated that CHM is almost always p57-negative, with only rare examples (0.5 %) displaying aberrant (positive) p57KIP2 expression, which is attributable to retention of the maternal copy of chromosome 11. CHMs are androgenetic conceptions by definition, and the vast majority are monospermic (85 %) [4].

The rare examples of aberrant p57KIP2 expression in both CHM and PHM can be correctly classified using genotyping. The findings of Banet et al. demonstrated

| Table 2 Outcomes |
|------------------|
| #   | Author | N  | TP  | FP  | TN  | FN  | S   | NPV | PPV | LR + | LR - |
| 1   |        |     |     |     |     |     |     |     |     |     |      |
| 2   |        |     |     |     |     |     |     |     |     |     |      |
| 3   |        |     |     |     |     |     |     |     |     |     |      |
| 4   |        |     |     |     |     |     |     |     |     |     |      |

TP true positive, FP false positive, TN true negative, FN false negative, S sensitivity, E specificity, NPV negative predictive value, PPV positive predictive value, LR+ likelihood ratio
that p57^KIP2 IHC is extremely reliable for the diagnosis of CHM. Therefore, the algorithmic approach for the diagnosis of HM proposed in this study advocates that p57^KIP2 results be used to triage cases for genotyping because this technique provides a highly reliable method for accurately diagnosing CHM in routine practice using a single immunohistochemical stain, with very little risk of misclassification of CHM. Consequently, genotyping for CHM is not necessary in routine practice and can be reserved for problematic cases, such as when p57^KIP2 immunostaining is suboptimal or unsatisfactory or when there is a discrepancy between morphology and p57^KIP2 results. One exception would be the case of recurrent HM, which raises the possibility of familial biparental HM. Patients with this disorder can have multiple/recurrent CHMs that are morphologically, immunophenotypically, and clinically similar to conventional CHMs; specifically, they are p57-negative and appear to show a similar risk of persistent gestational trophoblastic disease but are characterized by biparental diploidy rather than androgenetic diploidy [4].

Therefore, genotyping is useful in any patient with recurrent HMs to determine if they represent the familial form. It is important to recognize that the biparental form exists so that the genotyping results of biparental diploidy are not used to reject a diagnosis of CHM when the morphology and/or p57^KIP2 results support a diagnosis of CHM [4]. Some studies [1, 4] have confirmed that p57^KIP2 immunostaining is a practical and accurate adjunct for the diagnosis of CHM and its mimics because this technique is a relatively simple, reliable, cost-efficient, and rapid procedure. Therefore, the most ideal method for correctly classifying all HMs and non-molar specimens is a combined approach that includes the correlation of morphological features, p57^KIP2 IHC, and molecular genotyping [4]. This combined approach is particularly important when evaluating difficult and challenging cases with discordant positive p57^KIP2 staining, when molecular techniques are still necessary [1]. The findings of Banet et al. also confirmed that p57^KIP2 IHC analysis is useful for identifying androgenetic/biparental mosaic/chimeric conceptions, which include uniformly androgenetic/biparental mosaic specimens without molar features (probably early forms of placental mesenchymal dysplasia, which is characterized by androgenetic/biparental mosaicism and a lack of trophoblastic hyperplasia), androgenetic/biparental mosaic specimens with a molar component (typically CHMs), and twin gestations composed of CHM and non-molar specimen components. Recognition of the discordant and divergent staining patterns in these specimens is key to correctly interpreting these complex specimens and is necessary for specific microdissection of the different components to assure accurate molecular genotyping [4]. Therefore, we decided to perform this systematic review and meta-analysis using the most definitive method to assess the accuracy of p57^KIP2 IHC compared with molecular genotyping for the diagnosis of CHM.

**Additional files**

**Additional file 1:** PRISMA-P recommendations. (DOC 83 kb)

**Additional file 2:** Search strategy for MEDLINE/PUBMED. (DOCX 11 kb)

**Abbreviations**

AUC: Area under the curve; CENTRAL: Cochrane Central Register of Controlled Trials; CHM: Complete hydatidiform mole; CI: Confidence interval; DNA: Deoxyribonucleic acid; DOR: Diagnostic odds ratio; eCHM: Early CHM; EMBASE: Excerpta Medica Database; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HA: Hydropic abortion; HLA: Human leukocyte antigen; HM: Hydatidiform mole; IHC: Immunohistochemistry; LILACS: Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud; LR: Likelihood ratio; MEDLINE: Medical Literature Analysis and Retrieval System Online; NPV: Negative predictive value; OA: Open Archives Initiative; PHM: Partial hydatidiform mole; PIRO: Population, index test, reference standard test, outcome; PPV: Positive predictive value; PRISMA-P: Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies; ROC: Receiver operating curve; SROC: Summary ROC; VMC: Villous mesenchymal cells

**Acknowledgements**

Not applicable.

**Funding**

This protocol has not received any kind of grant or funding (external or not).

**Availability of data and materials**

Not applicable. This manuscript does not contain any data.

**Authors’ contributions**

JMM, ARB, MPP, IEL, and EMW contributed to the conception of the study protocol and search strategy, which was refined by MPP and EMW. MPP, IEL, and EMW designed the statistical analysis plan. The manuscript was drafted by JMM, MPP, and IEL and was critically revised by EMW. JMM registered the protocol with the PROSPERO database. EMW and ARB reviewed the manuscript. All authors have approved the publication of the protocol.

**Authors’ information**

We chose not to inform.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable. This manuscript does not contain any data from any individual person.

**Ethics approval and consent to participate**

This study was presented and approved by the Ethical Committee of the Maternity School of Rio de Janeiro University. As this is a protocol manuscript, the consent to participate is not applicable.

**Author details**

1School of Medicine, Center for Biological and Health Sciences – CBBS, Caixa do Sul University – UCS, Rua Francisco Getúlio Vargas, 1130, Bloco S, Caixas do Sul, RS CEP 95070-560, Brazil. 2Maternity School, Federal University of Rio de Janeiro – UFRJ, Rua das Laranjeiras, 180, Rio de Janeiro, RJ CEP 22240-003, Brazil. 3School of Medicine, Federal University Fluminense – UFF, Niterói, RJ, Brazil. 4HIV/AIDS Research Laboratory – LPHA, Center for Biological and Health Sciences – CBBS, Caixas do Sul University – UCS, Rua Francisco Getúlio Vargas, 1130, Bloco 5, Sala 315, Caixas do Sul, RS CEP
References

1. Landolsi H, Missaoui N, Brahem S, Hmissa S, Gribaa M. Pathology—research and practice the usefulness of p57 KIP2 immunohistochemical staining and genotyping test in the diagnosis of the hydatidiform mole. Pathol Res Pract. 2011;207:498–504.

2. Popiolek DA, Yee H, Mittal K, Chitiboga L, Prinz MK, Caragine TA, Budimlija ZM. Multiplex short tandem repeat DNA analysis confirms the accuracy of p57 KIP2 immunostaining in the diagnosis of complete hydatidiform mole. Hum Pathol. 2006;37:1426–34.

3. Fukunaga M, Katabuchi H, Nagasaki T, Mikami Y, Minamiguchi S, Lage JM. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. Am J Surg Pathol. 2005;29(7):942–7.

4. Banet N, DeScipio C, Murphy KM, Beierl K, Adams E, Vang R, Ronnett BM. Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping. Mod Pathol. 2014;27(2):238–54.

5. Cochrane handbook for diagnostic test accuracy reviews. 2013;164

6. Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

7. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Bossuyt PM, QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.

8. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.

9. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.

10. Doebler P. mada: Meta-analysis of diagnostic accuracy. 2012. Available at http://r-forge.r-project.org/projects/mada/. Accessed 31 Aug 2016

11. Schiller I, Dendukuri N. HSROC: Joint meta-analysis of diagnostic test sensitivity and specificity with or without a gold standard reference test. R package version 2.1.8. 2015. Available at https://cran-project.org/web/packages/HSROC/citation.html. Accessed 31 Aug 2016

12. Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982–90.

13. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic accuracy evaluations. Stat Med. 2001;20(19):2865–84.

14. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:558–61.

15. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93.